Check 35,000+ stocks against 26 valuation models and 37 quality factors

Biomedico Hadarim Ltd (ITGMF) fair value: what the stock is really worth

As of Sep 18, 2026: fair value of Biomedico Hadarim Ltd $0.46, price $0.48, upside -3.2%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Industrials · US

Thin data Sep 24, 2026

Biomedico Hadarim Ltd

ITGMF · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.4600 · Fairly valued (−3%)

!Quality 43/100

!Expensive Growth (revenue 5y +3.7 %/yr)

!Loss-making · -130.8% net margin (TTM)

!negative free cash flow

!Mixed vs. peers (4/9)

!Narrow moat 8/100

!Insider activity 52/100

!Evidence only low, so the estimate is less certain

!Weak on valuation: 29 out of 100

26 models, one by oneBear $0.3000 to bull $0.5800 Growth analysisrevenue history, year by year Quality 43/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Biomedico Hadarim Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.4500 – $31.41 · fair‑value band $0.3000 – $0.5800 · the $0.4750 price screens above the $0.4600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Biomedico Hadarim in your weekly email

Every Wednesday you see whether Biomedico Hadarim is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Airengy Tech Ltd, a technology company, offers compression, expansion, and storage solutions for energy storage and energy efficiency applications in Israel. The company offers AirBattery, an energy storage system that is a combination of pumped hydro and compressed air energy storage to enable grid-scale energy storage. The company was formerly known as Augwind Energy Tech Storage Ltd and changed its name to Airengy Tech Ltd in February 2026. The company was incorporated in 2007 and is based in Yakum, Israel.

Stock analysis

Biomedico Hadarim Ltd (ITGMF) currently trades at $0.4750, while our model-based Fair Value estimate is $0.4600, implying the stock looks roughly 3.3% fairly valued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: $0.3000 (bear) to $0.5800 (bull), the price of $0.4750 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Industrials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Biomedico Hadarim Ltd reported revenue of 12.2M ILS in FY2025 versus 1.8M ILS in FY2021, a compound +62.2%/yr. Reported net income was −15.9M ILS in FY2025.

Key figures

Market cap $13.1M · P/S ratio 1.13 · EPS (TTM) $−0.2100 · Net margin −131% · Return on equity −32.3% · Return on assets (EBIT) −38.6% · Revenue (TTM) $11.6M · Revenue growth (YoY) +11.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 5% below its 52-week high, currently above its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −49% fair-value upside, at −3%, ITGMF screens cheaper than that median.

Fair Value models

Bear $0.3000 Fair Value $0.4600 Bull $0.5800

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) $0.7800 $1.05 $1.56 51

All 1 models by family

Asset-Based

NCAV (Graham) $0.7800 $1.05 $1.56 51

Open the full fair value analysis →

Notify me when ITGMF reaches fair value

Put ITGMF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 43 · Market factors (momentum, volatility) 42

Profitability 5

Margins and returns on capital today

Quality Growth 31

Are margins and returns improving?

Cashflow 6

Earnings quality: real cash, not paper profit

Fin. Strength 75

Balance sheet, leverage, solvency risk

Investment 91

Disciplined investing over empire-building

Low Volatility 66

Calm price path (market factor)

Momentum 40

Price trend over the last 3–12 months (market factor)

52W Momentum 17

Distance to the 52-week high (market factor)

Net Issuance 78

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 14/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

−13.1%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+42.0%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.7%

Start year 2020 (pandemic)

Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+56.7%

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−225.9% (2020) → −143.0% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

Watch ITGMF, get fair value alerts →

Compare Biomedico Hadarim Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Industrial Machinery · 833 stocks

Beats the industry median on 4/8 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 43 · Bottom 25%

Fair Value upside −3% · Above median

Profitability

Return on assets −17% · Bottom 25%

Net margin (TTM) −131% · Bottom 25%

Operating margin (TTM) 0% · Bottom 25%

Growth and dividend

Revenue growth 12% · Above median

Valuation Multiplesvs Specialty Industrial Machinery median · lower = cheaper

P/B 0.30× · Cheapest 25%

P/S (TTM) 1.13× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)29 · sector 0

FUTURE (revenue growth)59 · sector 22

PAST (return on equity)0 · sector 28

HEALTH (low debt)0 · sector 95

DIVIDEND (yield)0 · sector 24

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Industrial Machinery stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
GE Vernova Inc GEV	$950.28	$194.25	−80%
SIE SIE	€273.85	€150.21	−45%
Eaton Corporation ETN	$442.49	$172.75	−61%
Parker-Hannifin Corporation PH	$964.85	$418.76	−57%
Cummins Inc CMI	$526.13	$359.38	−32%
Illinois Tool Works Inc ITW	$270.47	$151.39	−44%
Emerson Electric Co EMR	$154.19	$62.15	−60%
AMETEK, Inc AME	$245.41	$125.80	−49%
Rockwell Automation, Inc ROK	$427.19	$138.24	−68%
Sandvik AB SAND	kr 385.10	kr 199.07	−48%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biomedico Hadarim Ltd · Fair Value
$0.4600 −3%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/ITGMF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Biomedico Hadarim Ltd · Fair Value</span><br><b style="font-size:20px">$0.4600</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−3%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Biomedico Hadarim Ltd Fair Value". https://www.fairvalue-calculator.com/stock/ITGMF

Frequently asked questions

Is Biomedico Hadarim Ltd (ITGMF) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $0.4600 versus a price of $0.4750, about −3% upside (fairly valued).

What is the fair value of ITGMF?

Our model-based fair value for Biomedico Hadarim Ltd is $0.4600 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.4750.

What is the quality score of ITGMF?

Biomedico Hadarim Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Biomedico Hadarim Ltd (ITGMF)?

Our model-based price target is the fair value of $0.4600 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.3000, optimistic scenario $0.5800. It is a calculation from audited fundamentals, not an analyst target.

What is the Biomedico Hadarim Ltd stock forecast for 2026?

Our models put fair value at $0.4600, about −3% upside versus a price of $0.4750 (fairly valued). Cautious scenario $0.3000, optimistic scenario $0.5800. The calculation is refreshed regularly with new filings.

What is the revenue of Biomedico Hadarim Ltd (ITGMF)?

Biomedico Hadarim Ltd reported trailing-twelve-month revenue of about $11.6M (latest available figure, as of Sep 24, 2026).

What is the intrinsic value of Biomedico Hadarim Ltd (ITGMF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biomedico Hadarim Ltd it is $0.4600 per share (as of Sep 24, 2026), against a price of $0.4750. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Biomedico Hadarim Ltd stock overvalued or undervalued in 2026?

As of Sep 24, 2026, ITGMF trades above its calculated fair value: price $0.4750, fair value $0.4600, a gap of about −3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of ITGMF?

No. The price is what the market pays today ($0.4750); the fair value is what the company's own numbers justify ($0.4600). For Biomedico Hadarim Ltd the two are $0.0150 per share apart. That gap is exactly why we show both numbers side by side.

How much is Biomedico Hadarim Ltd worth?

The market values Biomedico Hadarim Ltd at about $13.1M (market capitalisation, as of Sep 24, 2026). Per share that is $0.4750; our models calculate a fair value of $0.4600 per share.

What do the bullish and bearish scenarios say about ITGMF?

Our models span a range for Biomedico Hadarim Ltd: cautious scenario $0.3000, base $0.4600, optimistic $0.5800 per share (as of Sep 24, 2026, price $0.4750). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Biomedico Hadarim Ltd (ITGMF)?

Balance-sheet figures for Biomedico Hadarim Ltd (as of Sep 24, 2026): return on equity −32.3%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.

How far is ITGMF from its 52-week high?

Biomedico Hadarim Ltd trades at $0.4750, about 5% below its 52-week high of $0.5000 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4600 is for.

Which stocks are comparable to Biomedico Hadarim Ltd?

From the same area (Industrials) we also value GE Vernova Inc, SIE, Eaton Corporation, Parker-Hannifin Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Biomedico Hadarim Ltd stock attractive at the current price?

The data as of Sep 24, 2026: price $0.4750, calculated fair value $0.4600 (−3%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of ITGMF calculated?

We run Biomedico Hadarim Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4600, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. Biomedico Hadarim Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Biomedico Hadarim Ltd (ITGMF)?

The closing price on Sep 18, 2026 was $0.4750. Our model-based fair value is $0.4600, about −3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Biomedico Hadarim Ltd right now?

The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($0.3000 to $0.5800) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Biomedico Hadarim Ltd

How large is the market capitalisation of Biomedico Hadarim Ltd (ITGMF)?

The market capitalisation of Biomedico Hadarim Ltd is $13.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Biomedico Hadarim Ltd (ITGMF)?

The price-to-sales ratio of Biomedico Hadarim Ltd is 1.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Biomedico Hadarim Ltd (ITGMF)?

Earnings per share at Biomedico Hadarim Ltd are $−0.2100. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Biomedico Hadarim Ltd (ITGMF)?

The net margin of Biomedico Hadarim Ltd is −131% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Biomedico Hadarim Ltd (ITGMF)?

The return on equity (ROE) of Biomedico Hadarim Ltd is −32.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Biomedico Hadarim Ltd (ITGMF)?

On an EBIT basis the return on assets of Biomedico Hadarim Ltd is −38.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

How fast is revenue growing at Biomedico Hadarim Ltd (ITGMF)?

Revenue at Biomedico Hadarim Ltd is growing +11.7% versus a year earlier (3y avg +42.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Biomedico Hadarim Ltd (ITGMF) generate?

The free cash flow of Biomedico Hadarim Ltd is −$13.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

Free · no account needed

Watch Biomedico Hadarim Ltd in the live analysis

One click puts Biomedico Hadarim Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.